Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 7/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.41 |
| ▸ | CCND1 | P24385 | 7/20 | 0.41 |
| ▸ | CDK2 | P24941 | 7/20 | 0.41 |
| ▸ | CCND3 | P30281 | 7/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28116991 | 0.85 | PDPK1 (0.52) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL17530935 | 0.84 | FGFR1 (0.41) | FGFR1FGFR2FGFR3KDRCDK4 | |
| SCHEMBL19057124 | 0.82 | FGFR1 (0.58) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL15796207 | 0.77 | FGFR1 (0.38) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL22356689 | 0.76 | FGFR1 (0.48) | FGFR1FGFR2FGFR3KDRCDK4 | |
| SCHEMBL17530959 | 0.75 | FGFR1 (0.58) | FGFR1KDR | |
| SCHEMBL5248615 | 0.73 | KDR (0.44) | FGFR1KDRCDK4CCNA2CCND1 | |
| SCHEMBL17530560 | 0.72 | FGFR1 (0.51) | FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL17531001 | 0.72 | HDAC6 (0.42) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL19019969 | 0.72 | KDR (0.51) | FGFR1FGFR2FGFR3KDRFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184521-B1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| EP-3184521-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016026445-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | 上海海和药物研究开发有限公司 | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR2 2/4885FGFR3 3/4885 |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR2 2/4885FGFR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.